Global Pharmaceutical Giants Report Strong 2025 Financial Results Amid Strategic Growth and Portfolio Diversification

Note: The fiscal year start dates of major companies differ from the calendar year, so there may be inconsistencies between fiscal quarters, fiscal years, and the calendar year.

United States

Eli Lilly Announces Q4 and Full-Year 2025 Results. Q4 revenue reached $19.292 billion, an increase of 43% compared to $13.533 billion in the same period last year. Quarterly operating profit was $8.373 billion, up 63% from $5.149 billion in the previous year. Quarterly net profit was $6.636 billion, a 50% increase from $4.41 billion the previous year. Full-year revenue amounted to $65.179 billion, a 45% increase from $45.043 billion the previous year. Annual operating profit totaled $26.302 billion, a 104% increase from $12.899 billion the previous year. Full-year net profit was $20.64 billion, a 95% increase from $10.59 billion the previous year.

Pfizer Announces Q4 and Full-Year 2025 Results. Q4 revenue was $17.557 billion, compared to $17.763 billion in the same period last year, a decrease of 1%. The company reported a net loss of $1.648 billion for the quarter, compared to a net profit of $410 million in the same period last year. Full-year revenue was $62.579 billion, down from $63.627 billion the previous year, representing a 2% decrease. Full-year net profit was $7.771 billion, down from $8.031 billion the previous year, a decrease of 3%.

AbbVie Announces Q4 and Full-Year 2025 Results. Q4 net revenue was $16.618 billion, compared to $15.102 billion in the same period last year. Quarterly operating profit was $4.544 billion, compared to an operating loss of $1.49 billion in the same period last year. Net profit attributable to the company for the quarter was $1.816 billion, compared to a net loss of $22 million in the same period last year. Full-year net revenue was $61.16 billion, compared to $56.334 billion last year. Full-year operating profit was $15.075 billion, compared to $9.137 billion last year. Full-year net profit attributable to the company was $4.226 billion, compared to $4.278 billion last year.

Johnson & Johnson Announces Q4 and Full-Year 2025 Results. Q4 Sales Reach $24.564 Billion, Up 9.1% from $22.52 Billion in the Same Period Last Year. Innovative Pharmaceutical Business Sales Hit $15.763 Billion, while Medical Technology Business Sales Reach $8.801 Billion. Quarterly Net Profit Surges to $5.116 Billion, a 49.1% Increase from $3.431 Billion the Previous Year. Full-Year Sales Amount to $94.193 Billion, a 6% Rise from $88.821 Billion the Prior Year. Annual Net Profit Soars to $26.804 Billion, Up 90.6% from $14.066 Billion the Previous Year. Innovative Pharmaceutical Business Records Sales of $60.401 Billion, with Medical Technology Business Sales at $33.792 Billion.

Merck & Co., Inc. Announces Q4 and Full-Year 2025 Results. Q4 sales were $16.4 billion, compared to $15.624 billion in the same period last year, representing a 5% increase. Pharmaceutical sales reached $14.843 billion, while animal health sales amounted to $1.505 billion. Quarterly net profit was $2.963 billion, down 21% from $3.743 billion in the same period last year. Full-year sales totaled $65.011 billion, up 1% from $64.168 billion the previous year. Annual net profit was $18.254 billion, a 7% increase from $17.117 billion the prior year. Pharmaceutical sales for the year reached $58.142 billion, with animal health sales at $6.354 billion.

Bristol Myers Squibb announced its financial results for the fourth quarter and full year of 2025. Total revenue for the fourth quarter was $12.502 billion, compared to $12.342 billion in the same period last year. Net profit attributable to the company for the quarter was $1.087 billion, compared to $72 million in the same period last year. Total revenue for the full year was $48.194 billion, compared to $48.3 billion last year. Net profit attributable to the company for the full year was $7.054 billion, compared to a net loss of $8.948 billion last year.

Amgen Announces Q4 and Full-Year 2025 Results. Total revenue for the fourth quarter was $9.866 billion, compared to $9.086 billion in the same period last year. Operating profit for the quarter was $2.72 billion, compared to $2.311 billion last year. Net profit for the quarter was $1.333 billion, compared to $627 million last year. Total revenue for the full year was $36.751 billion, compared to $33.424 billion last year. Full-year operating profit was $9.08 billion, compared to $7.258 billion last year. Full-year net profit was $7.711 billion, compared to $4.09 billion last year.

Gilead Sciences Announces Q4 and Full-Year 2025 Results. Total revenue for the fourth quarter was $7.925 billion, compared to $7.569 billion in the same period last year. Operating profit for the quarter was $1.984 billion, compared to $2.451 billion in the same period last year. Net profit attributable to the company for the quarter was $2.183 billion, compared to $1.783 billion in the same period last year. Total revenue for the full year was $29.443 billion, compared to $28.754 billion last year. Operating profit for the full year was $10.022 billion, compared to $1.662 billion last year. Net profit attributable to the company for the full year was $8.51 billion, compared to $0.48 billion last year.

Regeneron Pharmaceuticals announced its financial results for the fourth quarter and full year of 2025. Revenue for the fourth quarter was $3.884 billion, compared to $3.789 billion in the same period last year. Operating profit for the quarter was $880 million, compared to $990 million in the same period last year. Net profit for the quarter was $845 million, compared to $918 million in the same period last year. Full-year revenue was $14.343 billion, compared to $14.202 billion last year. Full-year operating profit was $3.578 billion, compared to $3.991 billion last year. Full-year net profit was $4.505 billion, compared to $4.413 billion last year.

Viatris Announces Q4 and Full-Year 2025 Financial Results. Total revenue for the fourth quarter was $3.704 billion, compared to $3.528 billion in the same period last year. Operating loss for the quarter was $193 million, compared to a loss of $180 million in the prior-year period. Net loss for the quarter was $340 million, compared to a net loss of $517 million in the same quarter last year. Full-year revenue was $14.343 billion, compared to $14.202 billion the previous year. Full-year operating loss was $2.663 billion, compared to a profit of $10.1 million the previous year. Full-year net loss was $3.515 billion, compared to a net loss of $634 million the previous year.

Vertex Pharmaceuticals Announces Q4 and Full-Year 2025 Results. Total revenue for Q4 was $3.19 billion, compared to $2.912 billion in the same period last year. Operating profit for the quarter was $1.206 billion, compared to $1.026 billion last year. Net profit for the quarter was $1.191 billion, compared to $913 million last year. Full-year total revenue reached $12 billion, up from $11.02 billion the previous year. Annual operating profit was $4.173 billion, compared to an operating loss of $233 million the previous year. Annual net profit was $3.953 billion, compared to a net loss of $536 million the previous year.

Biogen announced its financial results for the fourth quarter and full year of 2025. Total revenue for the fourth quarter was $2.279 billion, compared to $2.455 billion in the same period last year. The net loss attributable to the company for the quarter was $48.9 million, compared to a net profit of $267 million in the same period last year. Total revenue for the full year was $9.891 billion, compared to $9.676 billion last year. The net profit attributable to the company for the full year was $1.293 billion, compared to $1.632 billion last year.

Organon announced its financial results for the fourth quarter and full year of 2025. Revenue for the fourth quarter was $1.507 billion, compared to $1.592 billion in the same period last year. The net loss for the quarter was $205 million, compared to a net profit of $109 million in the same period last year. Full-year revenue was $6.216 billion, compared to $6.403 billion the previous year. Full-year net profit was $187 million, compared to $864 million the previous year.

Abbott Reports Q4 and Full-Year 2025 Results. Q4 net sales were $11.459 billion, compared to $10.974 billion in the same period last year. Quarterly net profit was $1.776 billion, compared to $9.229 billion last year. Specifically, nutrition business sales were $1.94 billion, diagnostics business sales were $2.457 billion, pharmaceuticals business sales were $1.382 billion, and medical device sales were $5.675 billion. Full-year total sales were $44.328 billion, compared to $41.95 billion last year. Full-year net profit was $6.524 billion, compared to $13.402 billion last year. Specifically, nutrition business sales were $8.451 billion, diagnostics business sales were $8.937 billion, pharmaceuticals business sales were $5.536 billion, and medical device sales were $31.387 billion.

Europe

Roche Group Announces 2025 Financial Results. Total annual sales reached 61.516 billion Swiss francs, compared to 60.495 billion Swiss francs in the previous year, representing a 2% increase. Annual operating profit was 18.476 billion Swiss francs, up from 13.417 billion Swiss francs the previous year, marking a 38% growth. Net profit attributable to shareholders of the company for the full year was 12.88 billion Swiss francs, compared to 8.277 billion Swiss francs the previous year, an increase of 56%. Pharmaceutical business sales amounted to 47.669 billion Swiss francs (approximately 60.4 billion US dollars), with an operating profit of 21.666 billion Swiss francs; Diagnostics business sales were 13.847 billion Swiss francs, with an operating profit of 1.07 billion Swiss francs.

AstraZeneca announced its financial results for the fourth quarter and full year of 2025. Total revenue for the fourth quarter was $15.503 billion, compared to $14.891 billion in the same period last year, representing a 4% year-over-year increase. Operating profit for the quarter was $2.978 billion, up 46% from $2.036 billion in the same period last year. Net profit after tax for the quarter was $2.329 billion, an increase of 55% from $1.5 billion in the same period last year. For the full year, total revenue was $58.739 billion, compared to $54.073 billion the previous year, marking a 9% year-over-year increase. Full-year operating profit was $13.743 billion, a 37% increase from $10.003 billion the previous year. Full-year net profit after tax was $10.233 billion, up 45% from $7.041 billion the previous year.

Novartis Reports Q4 and Full-Year 2025 Results. Q4 net sales were $13.336 billion, compared to $13.153 billion in the same period last year. Quarterly operating profit was $3.616 billion, compared to $3.53 billion last year. Quarterly net profit was $2.404 billion, compared to $2.82 billion last year. Full-year net sales were $54.532 billion, compared to $50.317 billion last year. Full-year operating profit was $17.644 billion, compared to $14.544 billion last year. Full-year net profit was $13.967 billion, compared to $11.939 billion last year.

Sanofi Announces Q4 and Full-Year 2025 Results. Q4 net sales were €11.303 billion (approximately $12.9 billion), compared to €10.564 billion in the same period last year, representing a 7% increase. Operating loss for the quarter was €1.038 billion, compared to an operating profit of €945 million in the same period last year. Net loss attributable to shareholders for the quarter was €801 million, compared to a net profit of €499 million in the same period last year. Full-year net sales were €43.626 billion (approximately $49.9 billion), compared to €41.081 billion last year. Full-year operating profit was €6.344 billion, compared to €7.252 billion last year. Full-year net profit attributable to shareholders was €7.813 billion, compared to €5.56 billion last year.

Novo Nordisk Announces Full-Year 2025 Results. Full-year net sales reached DKK 309.064 billion (approximately USD 47.3 billion), compared to DKK 290.403 billion in the previous year, representing a 6% increase. Full-year operating profit (EBIT) was DKK 127.658 billion, compared to DKK 128.339 billion in the prior year, marking a 1% decrease. Full-year net profit amounted to DKK 102.434 billion, up 1% from DKK 100.988 billion in the previous year.

GSK Releases Q4 and Full-Year 2025 Results. Q4 revenue reached £8.618 billion (approximately $11.4 billion), compared to £8.117 billion in the same period last year. Quarterly operating profit was £1.1 billion, up from £696 million the previous year. Net profit attributable to shareholders was £636 million, compared to £414 million the previous year. Full-year revenue amounted to £32.667 billion (approximately $43.3 billion), compared to £31.376 billion the previous year. Annual operating profit was £7.932 billion, compared to £4.021 billion the previous year. Net profit attributable to shareholders for the full year was £5.716 billion, compared to £2.575 billion the previous year.

Boehringer-Ingelheim will be released on March 25.

Bayer Group Announces 2025 Financial Results. Total group net sales for the year were €45.575 billion, compared to €46.606 billion in the previous year. The full-year EBIT loss was €1.077 billion, compared to a loss of €71 million in the previous year. The net loss attributable to shareholders of the company for the full year was €3.62 billion, compared to a net loss of €2.552 billion in the previous year. Among these figures, Crop Science division's full-year net sales were €21.678 billion, with an EBIT loss of €2.532 billion. Pharmaceuticals division's full-year net sales were €17.834 billion (approximately $20.4 billion), with an EBIT profit of €3.127 billion. Consumer Health division's full-year net sales were €5.808 billion, with an EBIT profit of €912 million.

German pharmaceutical and chemical giant Merck Group announced its 2025 financial results. Total net sales for the year reached €21.102 billion, compared to $21.156 billion in the previous year. Annual operating profit (EBIT) was €3.601 billion, versus €3.645 billion the previous year. Net profit after tax for the full year was €2.615 billion, down from €2.786 billion the prior year. Specifically, Life Science business net sales were €8.98 billion (approximately $10.3 billion), Healthcare business net sales were €8.607 billion (approximately $9.85 billion), and Electronics Technology business net sales were €3.515 billion.

Sandoz Announces Q4 and Full-Year 2025 Results. Q4 net sales were $3.029 billion, compared to $2.715 billion in the same period last year, representing a 12% increase. Full-year net sales reached $11.086 billion, up from $10.357 billion the previous year, marking a 7% growth. Full-year EBITDA was $1.98 billion, compared to $820 million the previous year. Full-year net profit was $914 million.

Fresenius Group Announces Q4 and Full-Year 2025 ResultsFresenius Group (FRESENIUS GROUP) announced its financial results for the fourth quarter and full year of 2025. In the fourth quarter, the group's revenue reached €5.875 billion, compared to €5.526 billion in the same period last year. The group's EBIT profit for the quarter was €713 million, with a net profit of €440 million. Fresenius Kabi reported revenue of €2.214 billion (approximately $2.535 billion), while Fresenius Helios Clinics generated revenue of €3.546 billion. For the full year, the group’s total revenue amounted to €22.554 billion, up from €21.526 billion the previous year. The group’s annual EBIT profit was €2.595 billion, with a net profit of €1.619 billion. Fresenius Kabi's annual revenue was €8.612 billion (approximately $9.859 billion), and Fresenius Helios Clinics reported revenue of €13.55 billion.

UCB Announces 2025 Financial Results. Full-year net sales reached €7.741 billion (approximately $8.863 billion), compared to $6.152 billion in the previous year. Adjusted EBIT for the full year was €2.009 billion, up from €836 million the previous year. Net profit attributable to shareholders for the full year was €1.558 billion, compared to €1.065 billion in the prior year.

Grifols Announces Q4 and Full-Year 2025 Results. Q4 net revenue reached €1.982 billion (approximately $2.27 billion), compared to €1.976 billion in the same period last year. Quarterly operating profit (EBIT) was €271 million, versus €372 million in the prior-year quarter. Quarterly group profit amounted to €98.14 million, up from €68.97 million in the same quarter last year. Full-year net revenue totaled €7.524 billion (approximately $8.614 billion), compared to €7.212 billion the previous year. Annual operating profit (EBIT) stood at €1.243 billion, an increase from €1.192 billion the previous year. Full-year group profit reached €402 million, significantly higher than €157 million in the prior year.

Specialty pharmaceutical company Ipsen announced its full-year 2025 financial results. Total sales for the year reached €3.676 billion (approximately $4.21 billion), compared to €3.401 billion in the previous year, representing an 8.1% increase. Core operating profit was €1.294 billion, up from €1.109 billion the previous year, marking a 16.7% growth. Core consolidated net profit was €1.009 billion, compared to €858 million the previous year, reflecting a 17.6% increase.

Asia-Pacific

Takeda Pharmaceutical Company Limited Announces Financial Results for the First Nine Months Ended December 31, 2025Revenue for the period was 3,411.2 billion yen (approximately 21.4 billion US dollars), compared to 3,528.2 billion yen in the same period last year, representing a year-on-year decrease of 3.3%. Operating profit was 422.382 billion yen, compared to 417.518 billion yen in the same period last year, marking a year-on-year increase of 1.2%. Net profit attributable to owners of the parent company was 216.081 billion yen, compared to 211.083 billion yen in the same period last year, reflecting a year-on-year increase of 2.4%.

Astellas Pharma Announces Nine-Month Results Ended December 31, 2025. Revenue for the period was 1,601.3 billion yen (approximately 10 billion USD), compared to 1,453 billion yen in the same period last year. Operating profit was 333.9 billion yen, compared to an operating loss of 22.48 billion yen in the previous year. Net profit attributable to owners of the parent company was 248 billion yen, compared to a net loss of 24.149 billion yen in the same period last year.

Daiichi Sankyo Company, Limited Announces Financial Results for the First Nine Months Ended December 31, 2025. Revenue for the period was 1,533.5 billion yen (approximately 9.61 billion US dollars), compared to 1,367.6 billion yen for the same period last year, representing a year-on-year increase of 12.1%. Operating profit was 233.8 billion yen, compared to 248.3 billion yen for the same period last year, marking a year-on-year decrease of 5.9%. Net profit attributable to owners of the parent company was 217.4 billion yen, compared to 208.6 billion yen for the same period last year, reflecting a year-on-year increase of 4.2%.

Otsuka Holdings announced its financial results for 2025. Annual revenue reached 2,468.9 billion yen, compared to 2,329.9 billion yen in the previous year, representing a 6% year-on-year increase. Annual operating profit was 479.4 billion yen, up 48.2% from 323.6 billion yen in the same period last year. Net profit attributable to the company's owners for the full year was 363.2 billion yen, compared to 343.1 billion yen in the previous year, marking a 5.8% year-on-year increase. Pharmaceutical business revenue amounted to 1,744.2 billion yen (approximately 10.9 billion U.S. dollars), with a profit of 402 billion yen. Nutrition business revenue was 577.7 billion yen, with a profit of 68.9 billion yen. Consumer products business revenue was 34.634 billion yen, with a profit of 25.171 billion yen.

Eisai Co., Ltd. Announces Financial Results for the First Nine Months Ended December 31, 2025. Revenue for the period was 619.95 billion yen (approximately US$3.885 billion), compared to 601.16 billion yen for the same period last year, representing a year-on-year increase of 3.1%. Operating profit amounted to 54.452 billion yen, compared to 55.402 billion yen for the same period last year, marking a year-on-year decrease of 1.7%. Net profit attributable to owners of the parent company was 41.808 billion yen, compared to 45.484 billion yen for the same period last year, reflecting a year-on-year decline of 8.1%.

Teva Pharmaceutical Industries announced its financial results for the fourth quarter and full year of 2025. Fourth-quarter net revenue was $4.711 billion, compared to $4.229 billion in the same period last year. Quarterly operating profit was $300 million, compared to an operating loss of $29 million in the same period last year. Quarterly net profit attributable to the company was $480 million, compared to a net loss of $217 million in the same period last year. Full-year net revenue was $17.258 billion, compared to $16.544 billion last year. Full-year operating profit was $2.157 billion, compared to an operating loss of $303 million last year. Full-year net profit attributable to the company was $1.41 billion, compared to a net loss of $1.639 billion last year.

CSL Group, an Australian biopharmaceutical company, announced its financial results for the first half of the fiscal year ended December 31, 2025. Revenue for the period was $8.332 billion, compared to $8.483 billion in the same period last year. Net profit attributable to shareholders for the period was $1.946 billion, compared to $2.074 billion in the same period last year.